Feasibility trial success could mean a new therapy, but not for a few years yet.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
A collection of all of Vantage's coverage from the 2019 European Society of Cardiology meeting.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Astrazeneca’s battle with Glaxosmithkline is set to ramp up next year with Breztri Aerosphere mortality data in COPD on the horizon.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.